Research letter
Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection

https://doi.org/10.1016/j.jaad.2022.05.005Get rights and content

Key words

alopecia areata
COVID-19 infection
JAK inhibitor
SARS-CoV-2
tofacitinib

Cited by (0)

Funding sources: None.

IRB approval status: Reviewed and approved by Columbia University’s Human Research Protection Office IRB (protocol # IRB-AAAT5890).

View Abstract
© 2022 by the American Academy of Dermatology, Inc.